medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2013, Number 4

<< Back Next >>

Rev Esp Med Quir 2013; 18 (4)

Comparative Results between the Intraarticular Application of Collagen PVP vs Hylan G-F 20 in Patients with Gonarthrosis

Leal OA, Mejía RLC, Benítez RA, Castillo RM

Language: Spanish
References: 19
Page: 306-311
PDF size: 387.99 Kb.


ABSTRACT

Background: Gonarthrosis is a multifactorial disease with a multidisciplinary treatment. Viscosupplementation is a line of treatment that seeks to restore the viscoelastic properties of the synovial fluid in order to balance synthesis and degradation of cartilage. Collagen PVP and Hylan G-F 20 have both different action mechanisms and have been used to complement the treatment of gonarthrosis.
Objective: To compare intraarticular application of collagen PVP and Hylan G-F 20 in patients with gonarthrosis.
Patients and method: A prospective, randomized, longitudinal and observational study was done, in which we recruited 80 patients with gonarthrosis grades ll or lll. The age range was between 35 and 55 years old and we randomized them into two groups containing 40 patients. Each group was treated with either collagen PVP or Hylan G-F 20. We registered their Lequesne index and visual analogue scale (VAS) score previous to start therapy, at one month and six months after finished treatment. In order to compare the results on both groups we used the X2 method.
Results: 65% of patients were women. For the group treated with collagen PVP the median of age was 48 years. The average of improvement was 3 points for the Lequesne index and 62.5% in the VAS score at six months. Whereas the group treated with Hylan G-F 20 had a median of age of 50 years, the average amelioration in the Lequesne index was 2.5 points and 55% at the VAS score at six months. According to the x2 test, the difference between these groups was statistically significant favoring collagen PVP (p › 0.05).
Conclusions: Both drugs show good results in the treatment of pain related to gonarthrosis, as well as improvement of the articular function. Application of collagen PVP showed a significant improvement regard to Hylan G-F 20 in the reduction of the Lequesne score; however, it has the disadvantage of requiring more intrarticular applications and, thus, it implies a higher cost treatment.


REFERENCES

  1. Langworthy MJ, Saad A, Langwhorty NM. Conservative treatment modalities and outcomes for osteoarthritis: the concomitant pyramid of treatment. Phys Sportsmed 2010;2:133-145.

  2. Arthritis Foundation. The facts about arthritis. Disponible en línea en: www.arthritis.org

  3. Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology 2005;44:7-16.

  4. Arango P. La viscosuplementación y sus efectos en la enfermedad articular. Ortho-tips AMOT 2012;8:80.

  5. Goldring M, Golding S. Osteoarthritis: current questions. J Cell Physiol 2007;213:626-634.

  6. Cahue S, Sharma L, Dunlop D, et al. The ratio of type ll collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage 2007;14:1087-1090.

  7. Aignet T, Martin J, et al. Osteoarthritis: aging of matrix and cells. Current Drug Targets 2007;8:325-331.

  8. Borzi RM, Mazzeti I. Chemokines in cartilage degradation. Clin Orthop Relat Res 2004;427:S53-S61.

  9. AOOS Clinical Guidelines. Treatment of osteoarthritis of the knee (non-arthroplasty). Rosemont: American Academy of Orthopaedic Surgeons, 2008.

  10. Cardona JI. La viscosuplementación como tratamiento alternativo en la osteoartritis. Ortho-tips AMOT 2012;8:87- 92.

  11. Divine JG, Zazulak B. Viscosuplementation for knee osteoarthritis: a systematic review. Clin Orthop Relat Res 2007;455:113-122.

  12. Complete Prescribing Information for SYNVISC, Laboratorio Genzyme. Disponible en línea: http://www.synviscone.com/ HCP/about/benefits.aspx

  13. Bagga H, Burkhardt D, Sambrook P. Long-term effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Reumatol 2006;33:946-950.

  14. Furuzama J, Alcocer J, Diaz de Leon L. Collagen PVP decreases collagen turnover in synovial tissue cultures from rheumatoid arthritis patients. Ann NY Acad Sci 1999;878:508-602.

  15. Furuzawa-Carballeda J, Muñoz-Chablé O, Barrios-Payán J, et al. Effect of polymerized-type I colagen in knee osteoarthritis I. In vitro study. Eur J Clin Invest 2009;39:591-597.

  16. Suárez A, Salgado R, Zamira A, et al. Inducción del tejido de granulación por parte de Lassar vs colágena-polivinilpirrolidona en úlceras por insuficiencia venosa. Cir Plast 2004;14:5-13.

  17. Furuzawa-Carballeda J, Krötzsch E, Barile-Fabris L, Alcalá M, Espinosa-Morales R. Subcutaneous administration of collagen-polyvinylpyrrolidone down-regulates IL-1B, TNFa, ELAM-1 and VCAM-1 expression in scleroderma skin lesions. Clin Exp Dermatol 2005;30:83-86.

  18. Furuzama-Carballeda J, Muñoz Chablé O, Macías Hernández S. Efecto del colágeno polimerizado tipo l en osteoartritis de rodilla ll. Estudio in vivo. Eur J Clin Invest 2009;39:598-606.

  19. Magaña y Villa MC, Ontiveros Reyes E, Ramírez Calderón A. Uso del colágeno polimerizado tipo 1 en el tratamiento no quirúrgico de la gonartrosis. Experiencia en el IMSS. Ortho-tips AMOT 2012;8:103-110.




2020     |     www.medigraphic.com